Pharmaceutical Market Europe • June 2022 • 3
COMMENT
In our cover article this month, Danny Buckland looks at how pharma is bringing innovation to the patient journey. As he explains, the creativity that fires through a drug’s scientific phases – where structures are decoded and disease modifiers disguised with exquisite precision – should not end at proof of concept. The call is growing for creativity to be a core characteristic of every aspect of a drug’s journey.
Danny continues by saying that having funky ideas and colourful imagery is not enough, and how recent cognitive neuroscience insights are shining a fascinating light on how creativity can be applied across the pharmaceutical sector. Read more on page 30.
Also in this month’s issue, on page 16 we have an article from Takeda’s Peter Schnack, where he talks about the role of digital and data in pharma and how data is poised for its most propulsive role yet.
We also have an article that looks at redefining how pharma looks at rare diseases – why changing the standard of care for rare diseases involves changing the standard of diagnosis. According to Global Genes, it takes an average of 7.3 years for a person with a rare disease to get accurately diagnosed after seeing seven or more clinicians. Imagine if the second clinician was one who championed genetic testing as an early way to rule a rare disease in or out. Read more on page 22.
Looking ahead, our July/August issue will look at the impact of COVID-19 on communications excellence. With the onset of the pandemic, the needs and expectations of healthcare professionals shifted and the need for agility and innovation in communication increased. The article will explore the importance of analysing the target audience, creating clear, simple messaging and offering the right channel selection.
If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Journalist/editorial assistant
Fleur Jeffries
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2022 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW